Michael D. Fox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael D. Fox has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Srinivasan
Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2 shared publications Alexandra J. Borst
Division of Pediatric Hematology‐Oncology The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
2 shared publicationsDong Li
Center of Applied Genomics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
2 shared publicationsHakon Hakonarson
Comprehensive Vascular Anomalies Program Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
2 shared publicationsLea F. Surrey
Comprehensive Vascular Anomalies Program Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
2 shared publications- Mithulan Jegapragasan
University of Pittsburgh, Pittsburgh, PA
2 shared publications
Latest Publications
- Open Access
- 30 August 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (11) , e32015
Expansion of the Phenotype of Lymphatic Anomalies Caused by Somatic Activating BRAF Variant
Background: The somatic activating variant in BRAF (p.V600E) was recently described as a novel cause of macrocystic head and neck lymphatic malformations in three individuals. Other recent studies profiling the genetic causes of more complex lymphatic anomalies identified this same pathogenic BRAF variant. Our aim was to expand the phenotypic description of the somatic BRAF p.V600E variant in individuals with vascular anomalies.Procedure: We searched the database of individuals with vascular anomalies at our institution for those identified as having complex lymphatic anomalies and somatic BRAF p.V600E variants. A comprehensive retrospective review of identified individuals’ electronic health records was conducted.Results: Six individuals with complex lymphatic anomalies had the BRAF p.V600E variant. All individuals had diffuse lymphatic malformations and abnormal lymphatic conduction. The conduction abnormalities were observed only after surgical interventions in five of the patients, in some cases, manifesting years later. There was immense phenotypic heterogeneity within the cohort.Conclusions: Complex lymphatic anomalies are an important new phenotype associated with the pathogenic BRAF p.V600E variant. Even in initially asymptomatic individuals within this patient population, longitudinal follow‐up is necessary, and surgical intervention should be pursued with caution. Further investigation is needed to better understand the etiology of the conduction problems associated with this pathogenic variant to inform the multidisciplinary approach to treatment.
- 30 August 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (11) , e32015
Open AccessExpansion of the Phenotype of Lymphatic Anomalies Caused by Somatic Activating BRAF Variant
Background: The somatic activating variant in BRAF (p.V600E) was recently described as a novel cause of macrocystic head and neck lymphatic malformations in three individuals. Other recent studies profiling the genetic causes of more complex lymphatic anomalies identified this same pathogenic BRAF variant. Our aim was to expand the phenotypic description of the somatic BRAF p.V600E variant in individuals with vascular anomalies.Procedure: We searched the database of individuals with vascular anomalies at our institution for those identified as having complex lymphatic anomalies and somatic BRAF p.V600E variants. A comprehensive retrospective review of identified individuals’ electronic health records was conducted.Results: Six individuals with complex lymphatic anomalies had the BRAF p.V600E variant. All individuals had diffuse lymphatic malformations and abnormal lymphatic conduction. The conduction abnormalities were observed only after surgical interventions in five of the patients, in some cases, manifesting years later. There was immense phenotypic heterogeneity within the cohort.Conclusions: Complex lymphatic anomalies are an important new phenotype associated with the pathogenic BRAF p.V600E variant. Even in initially asymptomatic individuals within this patient population, longitudinal follow‐up is necessary, and surgical intervention should be pursued with caution. Further investigation is needed to better understand the etiology of the conduction problems associated with this pathogenic variant to inform the multidisciplinary approach to treatment.
- Open Access
- 22 March 2025
- Published by Wiley
Expansion of the Phenotype of Lymphatic Anomalies Caused by Somatic Activating BRAF Variant
Complex lymphatic anomalies are a morbid group of overlapping disorders associated with lymphatic malformations. Advancement in genetic testing has led to greater understanding of the etiologies of these diseases and other vascular malformations. The somatic activating variant in BRAF (p.V600E) was recently described as a novel cause of head and neck lymphatic malformations and attributed to more complex lymphatic anomalies. Here, we define the phenotype of complex lymphatic anomalies attributed to the somatic BRAF p.V600E variant in six individuals. These cases further highlight the phenotypic heterogeneity associated with this variant and suggest the value of molecular targeted pharmacotherapy.
- 22 March 2025
- Published by Wiley
Open AccessExpansion of the Phenotype of Lymphatic Anomalies Caused by Somatic Activating BRAF Variant
Complex lymphatic anomalies are a morbid group of overlapping disorders associated with lymphatic malformations. Advancement in genetic testing has led to greater understanding of the etiologies of these diseases and other vascular malformations. The somatic activating variant in BRAF (p.V600E) was recently described as a novel cause of head and neck lymphatic malformations and attributed to more complex lymphatic anomalies. Here, we define the phenotype of complex lymphatic anomalies attributed to the somatic BRAF p.V600E variant in six individuals. These cases further highlight the phenotypic heterogeneity associated with this variant and suggest the value of molecular targeted pharmacotherapy.
- 17 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31661
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
- 17 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31661
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
- 16 May 2020
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (3) , 370-372
Chronic Meningitis Due to Prototheca zopfii in an Adolescent Girl
Prototheca species are unicellular, achlorophyllic algae that are ubiquitously distributed in nature [ 1]. Human protothecosis typically involves the cutaneous and subcutaneous tissues, and rarely causes systemic disease [ 2]. We report here a case of chronic meningitis due to Prototheca zopfii in an immunocompetent adolescent girl.
- 16 May 2020
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (3) , 370-372
Chronic Meningitis Due to Prototheca zopfii in an Adolescent Girl
Prototheca species are unicellular, achlorophyllic algae that are ubiquitously distributed in nature [ 1]. Human protothecosis typically involves the cutaneous and subcutaneous tissues, and rarely causes systemic disease [ 2]. We report here a case of chronic meningitis due to Prototheca zopfii in an immunocompetent adolescent girl.
- 1 May 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (5)
E-cigarette or Vaping Product Use–Associated Lung Injury (EVALI) Without Respiratory Symptoms
Electronic cigarette or vaping product use–associated lung injury (EVALI) is a newly emerging diagnosis in the United States, yet the incidence has surged greatly in the past year. With the trend of using electronic cigarettes (e-cigarettes) and vaping rising at an alarming rate among teenagers, many are resorting to friends, illicit drug dealers, and other informal sources to obtain their e-cigarettes, which is greatly contributing to the national outbreak of EVALI. The incidence of adolescents presenting with the constellation of respiratory, gastrointestinal, and constitutional symptoms characteristic of EVALI has been widely reported within the nation. We present one such case of an adolescent boy with a 2-year history of daily vaping who presented with nausea, vomiting, weight loss, and fever but lacked the respiratory symptoms that have been reported in the majority of EVALI cases reported thus far. Computed tomography scan of the abdomen and pelvis revealed an incidental finding of lung pathology characteristic of EVALI, prompting further workup and diagnosis of EVALI. In this case, it is demonstrated that the presentation of EVALI can be variable and is still poorly defined. The rising morbidity and mortality from EVALI reveal the importance of considering EVALI in all patients with a history of vaping or e-cigarette use, regardless of the presence or absence of respiratory symptoms.
- 1 May 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (5)
E-cigarette or Vaping Product Use–Associated Lung Injury (EVALI) Without Respiratory Symptoms
Electronic cigarette or vaping product use–associated lung injury (EVALI) is a newly emerging diagnosis in the United States, yet the incidence has surged greatly in the past year. With the trend of using electronic cigarettes (e-cigarettes) and vaping rising at an alarming rate among teenagers, many are resorting to friends, illicit drug dealers, and other informal sources to obtain their e-cigarettes, which is greatly contributing to the national outbreak of EVALI. The incidence of adolescents presenting with the constellation of respiratory, gastrointestinal, and constitutional symptoms characteristic of EVALI has been widely reported within the nation. We present one such case of an adolescent boy with a 2-year history of daily vaping who presented with nausea, vomiting, weight loss, and fever but lacked the respiratory symptoms that have been reported in the majority of EVALI cases reported thus far. Computed tomography scan of the abdomen and pelvis revealed an incidental finding of lung pathology characteristic of EVALI, prompting further workup and diagnosis of EVALI. In this case, it is demonstrated that the presentation of EVALI can be variable and is still poorly defined. The rising morbidity and mortality from EVALI reveal the importance of considering EVALI in all patients with a history of vaping or e-cigarette use, regardless of the presence or absence of respiratory symptoms.
- 20 June 2018
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 27 (18) , 3272-3282
TNNT1 nemaline myopathy: natural history and therapeutic frontier
We describe the natural history of 'Amish' nemaline myopathy (ANM), an infantile-onset, lethal disease linked to a pathogenic c.505G>T nonsense mutation of TNNT1, which encodes the slow fiber isoform of troponin T (TNNT1; a.k.a. TnT). The TNNT1 c.505G>T allele has a carrier frequency of 6.5% within Old Order Amish settlements of North America. We collected natural history data for 106 ANM patients born between 1923 and 2017. Over the last two decades, mean age of molecular diagnosis was 16 ± 27 days. TNNT1 c.505G>T homozygotes were normal weight at birth but failed to thrive by age 9 months. Presenting neonatal signs were axial hypotonia, hip and shoulder stiffness, and tremors, followed by progressive muscle weakness, atrophy and contractures. Affected children developed thoracic rigidity, pectus carinatum and restrictive lung disease during infancy, and all succumbed to respiratory failure by 6 years of age (median survival 18 months, range 0.2-66 months). Muscle histology from two affected children showed marked fiber size variation owing to both Type 1 myofiber smallness (hypotrophy) and Type 2 fiber hypertrophy, with evidence of nemaline rods, myofibrillar disarray and vacuolar pathology in both fiber types. The truncated slow TNNT1 (TnT) fragment (p.Glu180Ter) was undetectable in ANM muscle, reflecting its rapid proteolysis and clearance from sarcoplasm. Similar functional and histological phenotypes were observed in other human cohorts and two transgenic murine models (Tnnt1-/- and Tnnt1 c.505G>T). These findings have implications for emerging molecular therapies, including the suitably of TNNT1 gene replacement for newborns with ANM or other TNNT1-associated myopathies.
- 20 June 2018
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 27 (18) , 3272-3282
TNNT1 nemaline myopathy: natural history and therapeutic frontier
We describe the natural history of 'Amish' nemaline myopathy (ANM), an infantile-onset, lethal disease linked to a pathogenic c.505G>T nonsense mutation of TNNT1, which encodes the slow fiber isoform of troponin T (TNNT1; a.k.a. TnT). The TNNT1 c.505G>T allele has a carrier frequency of 6.5% within Old Order Amish settlements of North America. We collected natural history data for 106 ANM patients born between 1923 and 2017. Over the last two decades, mean age of molecular diagnosis was 16 ± 27 days. TNNT1 c.505G>T homozygotes were normal weight at birth but failed to thrive by age 9 months. Presenting neonatal signs were axial hypotonia, hip and shoulder stiffness, and tremors, followed by progressive muscle weakness, atrophy and contractures. Affected children developed thoracic rigidity, pectus carinatum and restrictive lung disease during infancy, and all succumbed to respiratory failure by 6 years of age (median survival 18 months, range 0.2-66 months). Muscle histology from two affected children showed marked fiber size variation owing to both Type 1 myofiber smallness (hypotrophy) and Type 2 fiber hypertrophy, with evidence of nemaline rods, myofibrillar disarray and vacuolar pathology in both fiber types. The truncated slow TNNT1 (TnT) fragment (p.Glu180Ter) was undetectable in ANM muscle, reflecting its rapid proteolysis and clearance from sarcoplasm. Similar functional and histological phenotypes were observed in other human cohorts and two transgenic murine models (Tnnt1-/- and Tnnt1 c.505G>T). These findings have implications for emerging molecular therapies, including the suitably of TNNT1 gene replacement for newborns with ANM or other TNNT1-associated myopathies.
- 2 October 2017
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 38 (10) , 494-495
Case 6: Ascites in a 20-year-old Man with Dandy-Walker Syndrome, Hydrocephalus, and Ventriculoperitoneal Shunt
1. Hyojeong Han, MD* 2. Kristen Critelli, MD† 3. Amy W. Davis, MD‡ 4. James E. Squires, MD† 5. Michael D. Fox, MD* 1. *Department of Pediatrics, 2. †Department of Pediatric Gastroenterology, Hepatology, and Nutrition, and 3. ‡Department of Pediatric Pathology, Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA A 20-year-old man with Dandy-Walker syndrome, cerebral palsy, epilepsy, and congenital hydrocephalus with ventriculoperitoneal (VP) shunt presents with 4 months of progressive abdominal distention and 1 day of lower-extremity swelling. Treatment for constipation was tried before his presentation, with no improvement. He is uncomfortable when supine, which his mother attributes to the abdominal fullness. Otherwise, he has been asymptomatic. Physical examination is notable for a distended abdomen and pitting edema up to his ankles. There is no dyspnea and no stigmata of chronic liver disease. Laboratory evaluation is notable for a hemoglobin level of 10.5 g/dL (105.0 g/L), an albumin level of 2.0 g/dL (20.0 g/L), a total protein level of 5.2 g/dL (52.0 g/L), and an erythrocyte sedimentation rate of 39 mm/hour. Results of additional studies, including serum electrolytes, liver function, kidney function, thyroid hormones, coagulation profile, urinalysis, pancreatic enzymes, serum uric acid, serum lactate dehydrogenase, serum ceruloplasmin, and serum α1-antitrypsin levels, are all normal. Tuberculin skin test results are negative at 48 hours. Abdominal ultrasonography shows a large amount of fluid throughout the abdomen and pelvis, with coarse echotexture of the liver but patent hepatic vessels with normal directional flow (Fig 1). Computed tomographic (CT) scan of the abdomen is notable for a large volume of ascites but normal intra-abdominal organs, including the liver and spleen (Fig 2). Paracentesis …
- 2 October 2017
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 38 (10) , 494-495
Case 6: Ascites in a 20-year-old Man with Dandy-Walker Syndrome, Hydrocephalus, and Ventriculoperitoneal Shunt
1. Hyojeong Han, MD* 2. Kristen Critelli, MD† 3. Amy W. Davis, MD‡ 4. James E. Squires, MD† 5. Michael D. Fox, MD* 1. *Department of Pediatrics, 2. †Department of Pediatric Gastroenterology, Hepatology, and Nutrition, and 3. ‡Department of Pediatric Pathology, Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA A 20-year-old man with Dandy-Walker syndrome, cerebral palsy, epilepsy, and congenital hydrocephalus with ventriculoperitoneal (VP) shunt presents with 4 months of progressive abdominal distention and 1 day of lower-extremity swelling. Treatment for constipation was tried before his presentation, with no improvement. He is uncomfortable when supine, which his mother attributes to the abdominal fullness. Otherwise, he has been asymptomatic. Physical examination is notable for a distended abdomen and pitting edema up to his ankles. There is no dyspnea and no stigmata of chronic liver disease. Laboratory evaluation is notable for a hemoglobin level of 10.5 g/dL (105.0 g/L), an albumin level of 2.0 g/dL (20.0 g/L), a total protein level of 5.2 g/dL (52.0 g/L), and an erythrocyte sedimentation rate of 39 mm/hour. Results of additional studies, including serum electrolytes, liver function, kidney function, thyroid hormones, coagulation profile, urinalysis, pancreatic enzymes, serum uric acid, serum lactate dehydrogenase, serum ceruloplasmin, and serum α1-antitrypsin levels, are all normal. Tuberculin skin test results are negative at 48 hours. Abdominal ultrasonography shows a large amount of fluid throughout the abdomen and pelvis, with coarse echotexture of the liver but patent hepatic vessels with normal directional flow (Fig 1). Computed tomographic (CT) scan of the abdomen is notable for a large volume of ascites but normal intra-abdominal organs, including the liver and spleen (Fig 2). Paracentesis …
- 30 January 2017
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 17 (5) , e373-e378
Making Residents Part of the Safety Culture: Improving Error Reporting and Reducing Harms
Objectives: Reporting medical errors is a focus of the patient safety movement. As frontline physicians, residents are optimally positioned to recognize errors and flaws in systems of care. Previous work highlights the difficulty of engaging residents in identification and/or reduction of medical errors and in integrating these trainees into their institutions’ cultures of safety. Methods: The authors describe the implementation of a longitudinal, discipline-based, multifaceted curriculum to enhance the reporting of errors by pediatric residents at Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center. The key elements of this curriculum included providing the necessary education to identify medical errors with an emphasis on systems-based causes, modeling of error reporting by faculty, and integrating error reporting and discussion into the residents’ daily activities. The authors tracked monthly error reporting rates by residents and other health care professionals, in addition to serious harm event rates at the institution. Results: The interventions resulted in significant increases in error reports filed by residents, from 3.6 to 37.8 per month over 4 years (P < 0.0001). This increase in resident error reporting correlated with a decline in serious harm events, from 15.0 to 8.1 per month over 4 years (P = 0.01). Conclusions: Integrating patient safety into the everyday resident responsibilities encourages frequent reporting and discussion of medical errors and leads to improvements in patient care. Multiple simultaneous interventions are essential to making residents part of the safety culture of their training hospitals.
- 30 January 2017
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 17 (5) , e373-e378
Making Residents Part of the Safety Culture: Improving Error Reporting and Reducing Harms
Objectives: Reporting medical errors is a focus of the patient safety movement. As frontline physicians, residents are optimally positioned to recognize errors and flaws in systems of care. Previous work highlights the difficulty of engaging residents in identification and/or reduction of medical errors and in integrating these trainees into their institutions’ cultures of safety. Methods: The authors describe the implementation of a longitudinal, discipline-based, multifaceted curriculum to enhance the reporting of errors by pediatric residents at Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center. The key elements of this curriculum included providing the necessary education to identify medical errors with an emphasis on systems-based causes, modeling of error reporting by faculty, and integrating error reporting and discussion into the residents’ daily activities. The authors tracked monthly error reporting rates by residents and other health care professionals, in addition to serious harm event rates at the institution. Results: The interventions resulted in significant increases in error reports filed by residents, from 3.6 to 37.8 per month over 4 years (P < 0.0001). This increase in resident error reporting correlated with a decline in serious harm events, from 15.0 to 8.1 per month over 4 years (P = 0.01). Conclusions: Integrating patient safety into the everyday resident responsibilities encourages frequent reporting and discussion of medical errors and leads to improvements in patient care. Multiple simultaneous interventions are essential to making residents part of the safety culture of their training hospitals.
- 1 January 2012
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 80 (1) , 398-409
Interleukin-23-Mediated Inflammation in Pseudomonas aeruginosa Pulmonary Infection
Pseudomonas aeruginosais an opportunistic pathogen that is capable of causing acute and chronic pulmonary infection in the immunocompromised host. In the case of cystic fibrosis (CF), chronicP. aeruginosainfection causes increased mortality by promoting overly exuberant airway inflammation and cumulative lung damage. Identifying the key regulators of this inflammation may lead to the development of new therapies that improveP. aeruginosa-related mortality. We report here that interleukin-23 (IL-23), the cytokine most clearly tied to IL-17-mediated inflammation, also promotes IL-17-independent inflammation duringP. aeruginosapulmonary infection. During the early innate immune response, prior to IL-17 induction, IL-23 acts synergistically with IL-1β to promote early neutrophil (polymorphonuclear leukocyte [PMN]) recruitment. However, at later time points, IL-23 also promoted IL-17 production by lung γδ T cells, which was greatly augmented in the presence of IL-1β. These studies show that IL-23 controls two independent phases of neutrophil recruitment in response toP. aeruginosainfection: early PMN emigration that is IL-17 independent and later PMN emigration regulated by IL-17.
- 1 January 2012
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 80 (1) , 398-409
Interleukin-23-Mediated Inflammation in Pseudomonas aeruginosa Pulmonary Infection
Pseudomonas aeruginosais an opportunistic pathogen that is capable of causing acute and chronic pulmonary infection in the immunocompromised host. In the case of cystic fibrosis (CF), chronicP. aeruginosainfection causes increased mortality by promoting overly exuberant airway inflammation and cumulative lung damage. Identifying the key regulators of this inflammation may lead to the development of new therapies that improveP. aeruginosa-related mortality. We report here that interleukin-23 (IL-23), the cytokine most clearly tied to IL-17-mediated inflammation, also promotes IL-17-independent inflammation duringP. aeruginosapulmonary infection. During the early innate immune response, prior to IL-17 induction, IL-23 acts synergistically with IL-1β to promote early neutrophil (polymorphonuclear leukocyte [PMN]) recruitment. However, at later time points, IL-23 also promoted IL-17 production by lung γδ T cells, which was greatly augmented in the presence of IL-1β. These studies show that IL-23 controls two independent phases of neutrophil recruitment in response toP. aeruginosainfection: early PMN emigration that is IL-17 independent and later PMN emigration regulated by IL-17.
- 30 June 2010
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 45 (6) , 1165-1168
A review of laparoscopic Nissen fundoplication in children weighing less than 5 kg
- 30 June 2010
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 45 (6) , 1165-1168
A review of laparoscopic Nissen fundoplication in children weighing less than 5 kg